ISPOR 14th Annual European Congress

5–8 November 2011
Hotel Auditorium Madrid
Madrid, Spain

Rational Health Care Decision Making
in Challenging Economic Times

Call for Abstracts

Congress Program Committee

Program Committee Chair
Xavier Badia, PhD, MD, MPH, Global Leader, Observational COE, Senior Principal, HEOR, IMS Health, Barcelona, Spain

Research Review Committee Co-Chairs
Jan J.V. Busschbach, PhD, Interim Director, Department of Medical Psychology & Psychotherapy, Erasmus MC, Rotterdam, The Netherlands
Dominik Gołicki, MD, PhD, MA, Partner, HealthQuest spr z o.o., Warsaw, Poland
Michael Schlander, PhD, MD, MBA, Chairman and Scientific Director, Institute for Innovation & Valuation in Health Care (InnoVal), Wiesbaden, Germany
Erkki Soini, MSc, RN, Chief Executive Officer, ESiOR Ltd., Kuopio, Finland

Workshop Review Committee Co-Chairs
Fernando Antoñanzas, MA, PhD, Economist, Department of Economics, University of La Rioja, Logrono, Spain

ABSTRACT SUBMISSION OPENS: 21 MARCH 2011
ABSTRACT SUBMISSION DEADLINE: 21 JUNE 2011
EARLY REGISTRATION DEADLINE: 20 SEPTEMBER 2011

Nancy Devlin, PhD, Research Director, Office of Health Economics, London, UK

Issue Panel Review Committee Co-Chairs
Peter Hertzman, PhD, Executive Director, HEOR, BMS Europe, Rueil Malmaison, France
Jacco Keja, PhD, Regional Leader, EMEA, HEOR, IMS Health, London, UK and Lecturer in Life Sciences Pricing and Management, Institute for Health Policy and Management, Erasmus University, Rotterdam, The Netherlands

Decision-maker Case Study Committee Co-Chairs
Julio López Bastida, MSc, PhD, Deputy Director, Health Technology Assessment Unit, Canary Islands Health Service, Tenerife, Spain
Antoni Gilabert Porràmon, PharmD, Managing Director of Pharmaceutical Care and Complementary Benefits, Catalan Health Service, Department of Health and Social Security, Government of Catalonia, Barcelona, Spain

Congress Promotional Opportunities

Exhibit
Register now! Over 2900 attendees in 2010!
Present your products and services to key outcomes researchers and health care decision-makers in pharmaceutical, medical device & diagnostics, biotechnology industries, clinical practice, government agencies, academia, and health care organizations.
Benefits to Exhibitors:
• Listing & 1/4 page advertisement in the Program & Schedule of Events
• Listing & 1/4 page advertisement on the ISPOR website
• One complimentary registration per exhibit booth
• Pre-registrant mailing labels

Sponsor
Increase your visibility! Give your company increased prominence.
Benefits to Sponsors:
• Sponsorship recognition at the plenary sessions
• Event signage
• Preferential exhibit booth location
• Listing & 1/4 page advertisement in the Program & Schedule of Events
• Listing & 1/4 page advertisement on the ISPOR website
• One complimentary registration

Advertise
Advertise in the Program & Schedule of Events!
• Company promotion • Job opportunities • Publications • Journals
• Full page, full color cover advertising available
• 1/4, 1/2, and full page, one color advertising available. Prices start from $900.

For More Info: www.ISPOR.org

16 September 2011
Elements of Pharmaceutical/Biotech Pricing I – Introduction
This course discusses key terminology and issues in pricing decisions. It covers the tools to build and document product value, the role of pharmacoeconomics and the differences in payment systems that help shape pricing decisions.

Meta-Analysis & Systematic Literature Review
This course covers 4 key areas: 1) impetus for network meta-analysis and systematic reviews; 2) basic steps to perform a quantitative systematic review; 3) statistical methods of combining data; and 4) appraisal and use of meta-analytic reports.

Applications in Using Large Databases in Europe
This course provides a review of European health care databases. Each database is discussed in-depth including directions on how to access the information and how researchers utilize this information.

NEW! Advanced Retrospective Database Analysis: Econometric Methods
This course will describe analytic techniques for estimation of treatment effects and statistical properties of estimators, ordinary least squares regression (OLS) and maximum likelihood estimation.

Patient Registries
Patient registries and their applications in identifying “real world” clinical, safety, and patient-perspective issues including safety and clinical objectives, as well as regulatory trends and requirements will be presented. Key operational components, management issues, and measures of program success are also discussed.

Utility Measurements (Preference-Based Techniques)
Methods for measuring preference-based outcomes are demonstrated, and important issues are discussed, such as potential insensitivity of generic instruments for disease-specific problems, and to what extent adaptation of generic or disease-specific quality of life instruments may offer a solution.

Pharmacoeconomic Modeling – Applications
During this course, students will have hands-on experience in constructing a decision analysis tree including Markov models, Monte Carlo simulations, sensitivity analysis, determination of probability values and transition probabilities.

New Discrete Event Simulation for Economic Analyses – Concepts
This course provides a basic understanding of the key concepts of discrete event simulation and will focus on the use of these simulation models to address health economic (and device-related) problems.

Bayesian Methods in Economic Evaluations – Introduction
This course reviews the Bayesian approach and its application to health economics and outcomes research and covers the basics of Bayesian statistics, the differences between Bayesian and classical approaches, and how to apply the Bayesian approach to clinical trials and cost-effectiveness analyses.

Statistical Methods for Pharmacoeconomics & Outcomes Research
This course discusses the foundations upon which major statistical tests are based and the application of these tests to pharmacoeconomic problems, and continues with detailed instruction for the use and application of statistical software, allowing students the opportunity for hands-on practice.

Cost-Effectiveness Analysis alongside Clinical Trials
This course presents design, conduct, and reporting of cost-effectiveness analyses alongside clinical trials. Analyses guided by an analysis plan and hypotheses, an incremental analysis using an intention to treat approach, characterization of uncertainty and standards for reporting results are presented.

Bayesian Methods in Economic Evaluations – Advanced
This course introduces the use of Bayesian methods in evidence synthesis and allows participants to gain hands-on experience using such modeling techniques within WinBUGS. Participants must bring a laptop with the latest, unrestricted version of WinBUGS pre-installed (download instructions will be provided).

Risk-Sharing/Performance-Based Arrangements for Drugs and Other Medical Products
Interest is growing among payers and producers of medical products for arrangements involving “pay-for-performance” or “risk-sharing”. Theory and practice are analyzed along with examples from Europe, the United States, and Australia.

Reimbursement Systems in Europe
This course reviews procedures employed by European health authorities to regulate market access based upon the appraisal of the clinical and economic value of new medical technologies.

Case Studies in Pharmaceutical/Biotech Pricing II – Advanced
Case studies lead participants through key steps of new product pricing, with a focus on the need to thoroughly analyze the business environment, and the need to closely integrate pricing, reimbursement and pharmacoeconomic strategies for the new product with clinical development and marketing strategies.

Transferability of Cost-Effectiveness Data between Countries
This course discusses factors making economic data more difficult to transfer from one country to another than clinical data, and focuses on the ISPOR Good Practices on Economic Data Transferability report.

Cost Estimation and Assessing Financial (Budget) Impact of New Health Care Technologies
Methods to determine costs associated with a health condition and the budget impact of new technologies, and incidence/prevalence-based costing strategies are presented. Treatment algorithms and event-based approaches and static and dynamic methods for estimating the budget impact of a new drug are discussed.

Advanced Patient-Reported Outcomes Assessment: Psychometric Methods
This course discusses psychometric analysis and the application of various techniques (structural equation modeling, factor analysis, and item response theory) in testing patient-reported outcomes instruments, measures and construct/criterion validity.

NEW! Conjoint Analysis – Theory & Methods
The conceptual and empirical basis for using conjoint analysis to elicit preferences in outcomes research, quantifying decision-maker preferences and the practical design and analytical issues that must be addressed to obtain valid empirical preference estimates are presented.

NEW! Network Meta-Analysis in Comparative Effectiveness Research
Network meta-analysis offers a quantitative method of integrating all data from available comparisons. Based in part on two ISPOR Task Force reports, the fundamentals and concepts of network meta-analysis will be presented and proposed.

Full Short Course descriptions at www.ispor.org
CALL FOR ABSTRACTS

ABSTRACT SUBMISSION BEGINS: 21 MARCH 2011 ■ ABSTRACT SUBMISSION DEADLINE: 21 JUNE 2011

SUBMISSION INSTRUCTIONS
All abstracts and proposals MUST be submitted through ISPOR’s online abstract submission system by 21 June 2011. Abstracts accepted for other ISPOR meetings can NOT be submitted and research published or presented at other national or international meetings is discouraged. SUBMISSION INSTRUCTIONS, EXAMPLES & SPECIFIC EVALUATION CRITERIA AVAILABLE AT www.ispor.org

RESEARCH ABSTRACTS
Outcomes research on all health care interventions (including drugs, devices, behavioral modification programs, surgery, disease prevention, gene therapy, screening, diagnostic procedures and health education) and on all diseases or health disorders are considered. Research abstracts (except for conceptual papers) must be organized by OBJECTIVES, METHODS, RESULTS, CONCLUSIONS. All accepted research abstracts are published in Value in Health as submitted. Accepted research is presented as a 15 minute podium presentation or poster presentation (with a poster author discussion hour). Abstracts are evaluated on the quality of the study (or concept) and quality of the abstract presentation. Research topics include: Clinical Outcomes Studies, Cost Outcomes Studies, Patient-Reported Outcomes/Preference-based Studies, Health Care Use & Policy Studies, Research on Methods, Conceptual Papers. See the ISPOR website for research subtopics, diseases and health care treatments.

HEALTH CARE DECISION-MAKER CASE STUDY ABSTRACTS
Health care decision-maker case study abstracts must describe an organization’s attempt to integrate cost or outcomes research information into their health care organization’s processes and procedures. Case Study abstracts must be organized: ORGANIZATION, PROBLEM OR ISSUE ADDRESSED, GOALS, OUTCOMES RESEARCH USED IN THE DECISION, RESULTS, LESSONS LEARNED. Negative as well as positive results are encouraged. Accepted case studies are presented as a 20 minute podium presentation or poster presentation (with a poster author discussion hour). THE PRESENTER MUST BE A HEALTH CARE DECISION-MAKER.

ISSUE PANEL PROPOSALS
Issue panel proposals should show real debate on new or controversial issues in health economics and outcomes research or real debate on the use of outcomes research in health care decision-making. Issue panel proposals must be organized MODERATOR, PANELISTS, ISSUE, OVERVIEW. An accepted issue panel is one hour in duration with a moderator and 2-3 panelists representing different organizations. Panelists should present distinct views about the topic. Issue Panel topics are: Clinical Outcomes Research Issues, Economic Outcomes Research Issues, Patient-Reported Outcomes Research Issues, Health Policy Development Using Outcomes Research Issues.

WORKSHOP PROPOSALS
Workshop proposals should show novel and innovative experiences in the conduct of outcomes research (including, but not limited to, experiences with conjoint analysis, large database analysis, modeling, observational studies, record review, surveys, sensitivity analysis and patient registries) or novel and innovative experiences in the use of outcomes research (clinical, economic, or patient-reported/preference-based outcomes) in health care policy development. Workshop proposals must be organized by DISCUSSION LEADERS, PURPOSE, DESCRIPTION. Accepted workshops are one hour in duration with a minimum of 2 and maximum of 4 discussion leaders (more than one organization must be represented). An audience interactive element must be included in the proposal and during the workshop. Workshop topics include: Clinical Outcomes Research, Economic Outcomes Research, Patient-Reported Outcomes/Preference-based Research, Use of Real World Data, Health Policy Development Using Outcomes Research.

PRELIMINARY PROGRAM

SUNDAY, 6 NOVEMBER: 12:00 – 20:00
FIRST PLENARY SESSION: CENTRALIZED EUROPEAN PRICING & REIMBURSEMENT AGENCY: SOMETHING TO STRIVE FOR OR AVOID AT ALL COSTS?
One of the goals of the European Union (EU), established in 1993, is the integration of processes which are common to all member countries. For example, the European Medicines Agency (EMA) is responsible for the evaluation of medicine applications for European marketing authorization. Under this centralised procedure companies submit a single marketing authorisation application to the Agency. Once granted, marketing authorisation is valid in all 27 EU member countries. Should an agency similar in structure to EMA be established with a centralized procedure for pricing and reimbursement? Should this be a decision making agency or only undertake health technology assessment? If the latter, what forms of evaluation should be undertaken? The pros and cons of such an agency will be debated.
* 5 Issue Panels * 14 Workshops * Exhibits * 350 Research Poster Presentations – Session I

MONDAY, 7 NOVEMBER: 8:00 – 19:00
SECOND PLENARY SESSION: THE REALITY OF REAL WORLD DATA AND ITS USE IN HEALTH CARE DECISIONS IN EUROPE
Initial decisions on reimbursement of a new technology usually include the extent to which it does more good than harm under ideal circumstances (efficacy). However, the goal is to determine the extent to which a technology does more good than harm under usual circumstances of health care practices [effectiveness]. How is this information on ‘usual circumstances of health care practices’ being collected, analyzed, and reported? Who is responsible for collecting, analyzing and reporting the information? Manufacturers? Government? During this session, the issues of collecting and analyzing real world data in Europe, such as patient registry data, reimbursement data, prospective observational studies, or other health care practice-based information will be presented. The question of who is responsible and the real use of this information in healthcare decision-making will be debated.
* 10 Issue Panels * 60 Research Podium Presentations * Exhibits * 350 Research Poster Presentations – Session II * Evening Social Event

TUESDAY, 8 NOVEMBER: 8:00 – 17:00
THIRD PLENARY SESSION: HETEROGENEITY IN THE COST-EFFECTIVENESS OF MEDICAL INTERVENTIONS: THE CHALLENGE OF MATCHING PATIENTS TO APPROPRIATE CARE
Inevitable variation between patients in the effects of disease and responses to treatment gives rise to heterogeneity in the benefits and costs of interventions. This heterogeneity challenges payers in selecting the most appropriate intervention given patients’ observed characteristics such as medical history and disease characteristics. The need to understand heterogeneity in the costs and benefits of interventions raises important methodological issues: how to make the best use of existing routinely available information to estimate costs and benefits in sub-groups of patients? how to establish the optimal number of patient sub-groups? the appropriate assessment of the additional information offered by diagnostic tests; and the implications of offering choice to patients and physicians to reveal information on the cost-effectiveness of therapies. During this session, these issues will be presented from the perspective of the researcher, the payer, and a manufacturer of companion diagnostic and drug combinations.
* 5 Issue Panels * 14 Workshops * ISPOR Group Forums * Exhibits * 350 Research Poster Presentations – Session III
ISPOR 14th Annual European Congress

5-8 November 2011 ■ Madrid, Spain

PAYMENT INFORMATION

Please enclose a check payable in US dollars or Euros to: International Society for Pharmacoeconomics and Outcomes Research or ISPOR and send to the ISPOR address given below or charge to: 

- VISA
- MasterCard
- American Express

Account Number: _______________________
Expiration Date: _______________________

Authorized Signature: _______________________

MAIL DETAILS: If not paying by credit card online, send registration form and payment to: International Society for Pharmacoeconomics and Outcomes Research 3100 Princeton Pike, Building 3 Suite E, Lawrenceville, New Jersey 08648, USA
Tel: 1-609-219-0773 Fax: 1-609-219-0774
E-mail: info@ispers.org Internet: www.ispor.org

PAYMENT DETAILS: Payment may be made by check, travelers check, bank transfer (there is a USD $40 charge) or credit card.

Visa, MasterCard, American Express will be charged in US dollars. Signature, account number and expiration date must be included. Non-US checks written in US$ on banks with a US counterpart are at no charge. For Non-US checks written in US$ on banks with NO US counterpart there is USD $25 charge. Phone charges will NOT be accepted.

If payment is being made by your company, please make sure your name is indicated on the check stub or correspondence.

For bank transfers, please designate the registration name and/or registration number.

MEMBERSHIP DETAILS: If ISPOR cannot verify your current membership, you will be charged the non-member registration rate. The Non-Member rate includes an annual ISPOR membership ($140/$35 Students), which includes a one year online subscription to Value in Health – The Journal of the International Society for Pharmacoeconomics and Outcomes Research.

"The Non-Member rate includes an annual ISPOR membership ($140/$35 Students).

"One Day Registration Details: One day registration does not include ISPOR membership benefits and cannot be combined.

CANCELLATION DETAILS: Cancellation fee before 20 September 2011 is US $145. No refunds given after 20 September 2011.

Online registration available at: www.ispor.org